Azura Ophthalmics
Steven Altschuler, M.D. brings over 20 years of experience building and leading world-class, integrated, translational, value-based health care systems and transformational biotechnology companies.
He currently serves as managing director of Healthcare Ventures at Ziff Capital Partners and was previously chair of the board of directors at Spark Therapeutics (now part of Roche) for six years, from its founding until it was acquired in 2019. In his role at Ziff Capital Partners, Dr. Altschuler co-leads the firm’s efforts towards investing in and facilitating the startup and development of, companies with potentially transformative technologies that emphasize cellular and molecular approaches to human disease.
He previously co-founded Spark Therapeutics to develop and commercialize the preclinical and clinical gene therapy programs advanced at the Children’s Hospital of Philadelphia (CHOP) and other institutions. He served as Spark’s board chair from its founding through its acquisition in 2019, which included leading the company through a successful transition to a public company and the launch of an approved commercial product, which was the first gene therapy for an inherited disease approved by the U.S. Food and Drug Administration and European Medicines Agency.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Azura Ophthalmics
1 followers
Azura Ophthalmics is a clinical-stage company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the United States. The company is developing an innovative portfolio of compounds to advance treatments for Meibomian gland dysfunction (MGD), the leading cause of Dry Eye Disease (DED). By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatment options are currently lacking.